Tampa, Fla. — The Obesity Action Coalition (OAC) commends the Biden Administration for raising awareness of the need to expand access to obesity care and reduce the high cost of obesity medications. President Biden’s recent announcement marks a significant step forward in a national effort to enhance care and support for individuals affected by obesity.
Read Article

Tampa, Fla., June 3, 2024—The Obesity Action Coalition (OAC) and the STOP Obesity Alliance are proud to announce the release of the “Medicaid Obesity Treatment Coverage Study.” This study is the first to analyze and investigate levels of state Medicaid coverage for obesity treatment options, beyond whether a benefit was covered or not. Healthcare plans
Read Article

Tampa, FL, May 28, 2024 – This week, the Obesity Action Coalition (OAC), along with 57 other organizations, delivered a letter to the Biden Administration to call on the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to provide access to comprehensive obesity care. The letter to
Read Article

The Obesity Action Coalition (OAC) is pleased to share that Boston Scientific has joined OAC’s Chairman’s Council at the Silver level! Thank you for committing to support and champion the OAC’s mission. About Boston Scientific As a global medical technology leader for more than 40 years, Boston Scientific transforms lives through innovative medical technologies that improve the health
Read Article

The Obesity Action Coalition (OAC) is pleased to share that Biohaven Pharmaceuticals has joined OAC’s Chairman’s Council at the Bronze level! Thank you for committing to support and champion the OAC’s mission. About Biohaven Pharmaceuticals Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including
Read Article

To kick off Women’s Health Month, OAC’s own Director of Policy Strategy and Alliances Tracy Zvenyach, PhD, MS, RN, and Immediate-past Chair Patty Nece, JD, participated in Exploring Obesity’s Impact on Women and Policy’s Role in Improving Outcomes, an insightful panel discussion hosted by Society for Women’s Health Research. The discussion focused on understanding and
Read Article

The Obesity Action Coalition, the Partnership to Advance Cardiovascular Health and more than 40 healthcare and advocacy organizations are urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and access to semaglutide for the treatment of obesity. We applaud CMS’s recent decision to cover obesity medications for patients with existing, high-risk cardiovascular
Read Article

Tampa, Fla. – The Obesity Action Coalition (OAC) condemns Minnesota minor league baseball team St. Paul Saints for naming their mascot ‘Ozempig’ and calls for an immediate change. The name mocks Ozempic, a medication primarily indicated for the treatment of diabetes but sometimes used off-label for the treatment of obesity. Diabetes and obesity affect millions
Read Article

The Obesity Action Coalition (OAC) is thrilled to announce James Zervios’s promotion to Chief Operating Officer! Throughout his nearly two decades with the OAC, James has demonstrated exceptional leadership and dedication, especially in the areas of OAC’s public awareness initiatives, educational content, and development. From his pioneering role in communications to his pivotal contributions in
Read Article

Obesity Care Week saw a powerful surge of momentum as the Obesity Action Coalition (OAC) mobilized over 60 dedicated advocates to Capitol Hill in Washington, DC! On Monday, March 4, 2024, we met with more than 70  Senators and Representatives to share our stories as patients who have been denied access to obesity care. We
Read Article

The anti-obesity medication Wegovy® has been approved by the US Food and Drug Administration (FDA) for cardiovascular risk reduction in people with overweight or obesity and an established cardiovascular disease. The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy® statistically significantly reduced the risk of major adverse cardiovascular events. Obesity
Read Article

  Tampa, Fla. – Today, Monday, March 4, marks the beginning of the 10th annual Obesity Care Week, a five-day public awareness campaign aiming to change the way we care by creating a society that understands, respects and accepts the complexities of the disease of obesity and prioritizes accessible, science-based treatment. With more than 130
Read Article